MarketWatch's own descriptionRapid weight loss can lead to issues with bone quality, particularly in older adults.
News
Energy and royalties news
Income paid for the use of something owned: mineral and music royalties, pipeline partnerships and resource leases.
- Dividends3016
- Rates and cash207
- Bonds and credit277
- REITs and property38
- Preferred stock0
- Funds and ETFs43
- Energy and royalties30
- Private credit51
Sources last checked Oct 10, 2026 at 02:05 UTC · newest headline in this topic 1 day ago. Showing the 30 most recent of 30 stored under energy and royalties.
What this page is, and what it is not
Every headline here is a link to the original publisher's page, and it opens there rather than on this site. We do not write the news and we do not rewrite it: the line under a headline is the publisher's own description of their article, shown as theirs. Items are selected by source and subject, not by whether we agree with them, and appearing in this list is not an endorsement of the publisher, the article or anything named in it.
Thursday, Oct 08, 2026
Wednesday, Oct 07, 2026
Barron's's own descriptionHess Midstream's deal with Chevron means lower earnings but also longer contracts, fewer shares outstanding, and expansion into a second region.
Tuesday, Oct 06, 2026
Reuters's own descriptionChevron said on Tuesday that several of its subsidiaries signed agreements with Hess Midstream to restructure their Bakken midstream contracts and create new midstream contracts…
Friday, Oct 02, 2026
CNBC's own descriptionEli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of…
Friday, Sep 25, 2026
CNBC's own descriptionNovo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market…
Monday, Sep 21, 2026
CNBC's own descriptionEli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July. In an exclusive interview…
CNBC's own descriptionEli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Sunday, Sep 13, 2026
CNBC's own descriptionThe ratings of these experts are backed by in-depth research of a company's financials, and thorough analysis of the factors affecting business performance.
Thursday, Sep 10, 2026
Barron's's own descriptionPipeline operator Energy Transfer and several associated companies will shift their stock listings from the NYSE to the Texas Stock Exchange.
Barron's's own descriptionEuropean natural gas prices are surging, creating opportunities for Venture Global, Cheniere Energy, Shell, Equinor and U.S. gas producers.
Wednesday, Sep 09, 2026
Reuters's own descriptionThe U.S. Justice Department is investigating whether Nvidia tried to skirt antitrust scrutiny of the chipmaker's licensing deal last year with AI chip startup Groq, the New York Times…
Tuesday, Sep 08, 2026
CNBC's own descriptionCNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market.
Monday, Aug 31, 2026
CNBC's own description"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Reuters's own descriptionPeople taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who…
Reuters's own descriptionTelehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international…
Thursday, Aug 27, 2026
Barron's's own descriptionDeutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growth and navigate an impending patent cliff.
Sunday, Aug 23, 2026
CNBC's own descriptionThe stakes are incredibly high for the U.S. to maintain its lead in data centers. It seems to be getting harder and harder in this election year.
Tuesday, Aug 18, 2026
Barron's's own descriptionAmylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.
Thursday, Aug 06, 2026
The Wall Street Journal's own descriptionNovo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo will be available at a cost of $50 a month.
Wednesday, Aug 05, 2026
MarketWatch's own descriptionThe Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.
CNBC's own descriptionBank of America CEO Brian Moynihan said the company is spending more than $250 million annually to provide GLP-1 weight loss medications to its workforce. Moynihan told CNBC the expense has…
The Wall Street Journal's own descriptionEli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs.
The Wall Street Journal's own descriptionCVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its…
Monday, Aug 03, 2026
Reuters's own descriptionWilliams said on Monday it would buy Momentum Midstream for $5.5 billion and raise its full-year profit outlook, expanding its natural gas network in the Haynesville shale to serve…
Saturday, Aug 01, 2026
CNBC's own descriptionAs employers drop GLP-1 coverage, more Americans are being encouraged to use direct-to-consumer (DTC) weight-loss drug prescription programs. Major retailers and pharmacy chains, from CVS…
Saturday, Jul 25, 2026
CNBC's own descriptionShipping and logistics companies are tapping into the growing healthcare market as cold chain and temperature-controlled facilities become more crucial. Those companies are investing…
Thursday, Jul 23, 2026
CNBC's own descriptionThe increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now…
Tuesday, Jul 21, 2026
MarketWatch's own descriptionThe drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
The Wall Street Journal's own descriptionThe maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
CNBC's own descriptionNovo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior…
The mechanics behind these headlines
A news feed tells you what happened. These pages explain how the instrument works, what it costs, how it is taxed and what can go wrong.
The current numbers for this corner of the market live in Royalties, which is built from the database rather than from headlines. The Learn pages below cover the terms a story in this topic is likely to use without defining them.
- Oil and gas royalty interests
- Mineral rights
- Master limited partnerships
- Royalty trusts
- Music royalties
- Royalties : the current data for this topic
- All income news : every topic, newest first
About these headlines
Headlines are supplied by third-party news feeds and can be incomplete, delayed or wrong, and
a publisher can update or withdraw a story after we have stored the link. Timestamps are the
publisher's own, normalised to UTC. Inclusion here is not an endorsement of the publisher or
the article, nothing in this feed has been verified by us, and nothing in it is a
recommendation to buy, sell or hold anything.
Only 72 named publishers can appear in this feed: wire services, mainstream business press, and specialist market titles. Press-release distribution wires, law-firm class-action solicitations, stock-promotion copy and syndication portals are blocked outright, including when they arrive under an allowed byline. Anything matching none of the income topics below is dropped rather than filed under a catch-all. The full allowlist is published on the news index.